Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder : a double-blind, randomised, placebo-controlled study [ISRCTN83050762] by Carey, Paul D. et al.
BioMed CentralBMC Psychiatry
ssOpen AcceResearch article
Quetiapine augmentation of SRIs in treatment refractory 
obsessive-compulsive disorder: a double-blind, randomised, 
placebo-controlled study [ISRCTN83050762]
Paul D Carey*1, Bavanisha Vythilingum1, Soraya Seedat1, 
Jacqueline E Muller1, Michael van Ameringen2 and Dan J Stein1
Address: 1MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa and 2Department of Psychiatry and 
Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
Email: Paul D Carey* - pcarey@sun.ac.za; Bavanisha Vythilingum - bv@sun.ac.za; Soraya Seedat - sseedat@sun.ac.za; 
Jacqueline E Muller - jemuller@sun.ac.za; Michael van Ameringen - vanamer@mcmaster.ca; Dan J Stein - djs2@sun.ac.za
* Corresponding author    
Abstract
Background: Although serotonin reuptake inhibitors are effective in the treatment of OCD,
many patients fail to respond to these agents. Growing evidence from open-label and placebo-
controlled trials suggests a role for augmentation of SRIs with atypical antipsychotics in OCD.
Quetiapine is generally well tolerated and previous open-label data has produced mixed results in
OCD and additional controlled data is needed.
Methods: We undertook a double-blind, randomised, parallel-group, flexible-dose, placebo-
controlled study of quetiapine augmentation in subjects who had responded inadequately to open-
label treatment with an SRI for 12 weeks. Following informed consent and screening, forty-two
subjects were randomised to either placebo or quetiapine for six weeks.
Results: There was significant improvement from baseline to endpoint on the Yale-Brown
Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p <
0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo
treated subjects being classified as responders. Quetiapine did not demonstrate a significant benefit
over placebo at the end of the six-week treatment period (p = .636). Similarly quetiapine failed to
separate from placebo in the subgroup of subjects (n = 10) with co-morbid tics. Quetiapine was
generally well tolerated.
Conclusions: In this study, quetiapine augmentation was no more effective than placebo
augmentation of SRIs. A number of limitations in study design make comparisons with previous
studies in this area difficult and probably contributed to our negative findings. Future work in this
important clinical area should address these limitations.
Published: 24 January 2005
BMC Psychiatry 2005, 5:5 doi:10.1186/1471-244X-5-5
Received: 12 October 2004
Accepted: 24 January 2005
This article is available from: http://www.biomedcentral.com/1471-244X/5/5
© 2005 Carey et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Psychiatry 2005, 5:5 http://www.biomedcentral.com/1471-244X/5/5Background
Obsessive-compulsive disorder (OCD) is a prevalent,
chronic and disabling disorder [1]. Controlled pharmaco-
therapy studies have established superiority of serotonin
re-uptake inhibitors (SRI's) over noradrenaline reuptake
inhibitors and over placebo in OCD and these currently
form the cornerstone of pharmacotherapy management
[2]. Despite the considerable advances made with the
introduction of the SRI's into clinical practice, 40–60% of
subjects still fail to respond adequately to initial therapy
[3,4].
From this it is clear that a need exists to pursue more effec-
tive treatments for those with OCD who fail to respond or
respond inadequately to SRI's. To this end, preliminary
evidence supports a role for the addition of atypical antip-
sychotics to SRIs in OCD. These agents combine serot-
onin-dopamine antagonism with the advantage of being
well tolerated including a low potential for inducing
motor side-effects.
To date a number of open-label studies have suggested
that augmenting SRI's with atypical antipsychotics is an
effective strategy for treatment-refractory OCD. These
include support for risperidone [5-7], olanzapine [8-13],
and more recently amisulpride [14] and quetiapine [15-
18]. A single open-label study using quetiapine as aug-
mentation showed lack of effect in a small sample using
low doses [19].
The outcome of the first controlled study in this area with
the antipsychotic haloperidol demonstrated preferential
benefit for refractory OCD subjects with co-morbid tic dis-
order [20]. In two subsequent studies the efficacy of risp-
eridone in SRI refractory OCD has also been reported
[21,22]. Interestingly the former study [21], did not repli-
cate the particular advantage for subjects with co-morbid
tic disorder. Efficacy has also been shown for quetiapine
[23] and olanzapine [24] using similar designs, but the
effects on co-morbid tic disorders were not reported. In
contrast a recent controlled study using olanzapine failed
to demonstrate efficacy over placebo in a six week study
[25].
Despite some mixed evidence in this area, in general the
available literature appears to support the use of relatively
short trials with low doses of antipsychotic agents as aug-
mentation to SRIs. Quetiapine has a particularly interest-
ing profile in that it is the only available antipsychotic
with significant 5-HT1D effects and this serotonin recep-
tor subtype has been implicated in OCD [26,27].
Our objective was to examine the effects of quetiapine
augmentation in subjects with OCD who had failed to
respond adequately to a 12 week trial of an SRI, employ-
ing a double-blind, placebo-controlled, six week study
design.
Methods
Patients
Forty two subjects aged 18–65 years inclusive were
recruited in our multi-centre study comprising five sites in
South Africa and one in Canada. Recruitment took place
between May 2002 and November 2003. Prior to com-
mencement, all sites in the study received approval from
their relevant Research Ethics committees/Institutional
review boards and regulatory authorities. All subjects pro-
vided written informed consent prior to the commence-
ment of any study-related procedures. Diagnosis was
confirmed using the MINI Neuropsychiatric Interview
(Version 5.00, 1998) [28] to ensure compatibility with the
Diagnostic and Statistical Manual for Mental Disorders,
Fourth Edition (DSM-IVTR)[29] criteria for OCD. Sub-
jects with any co-existing Axis I disorder were excluded
unless the co-morbid condition was deemed to be second-
ary to the OCD. Female subjects of childbearing potential
were required to use adequate contraception and were not
permitted to breastfeed while on the study. Subjects were
excluded if they suffered from unstable medical condi-
tions including renal or hepatic insufficiency, epilepsy or
had suffered previous brain injury or undergone brain sur-
gery. Taking medication that was deemed likely to interact
with quetiapine or any other psychoactive substance was
grounds for exclusion.
Study Design
All subjects were treated and monitored by investigators
for the minimum twelve week duration of SRI-alone treat-
ment phase before inclusion into this study. This was to
ensure that patients met criteria for duration of SRI treat-
ment which included at least 6 weeks on the maximum
tolerated dose of the relevant SRI. Sample size calcula-
tions were based conservatively on similar work in this
area [20,21]. Accordingly, for the primary outcome varia-
ble (YBOCS), clinically meaningful differences between
treatment groups of 6.67 with a standard deviation (SD)
of 6 would be detected with a power of 80% at a 5% sig-
nificance level with a sample size of 14 in each of the treat-
ment groups. The larger sample recruited reflects the
anticipation of a 33% drop-out rate in the double-blind
treatment phase.
A double-blind, randomised, parallel-group six-week aug-
mentation with quetiapine or matching placebo of the SRI
to which participants had not responded adequately, was
undertaken. Specific SRI's, mean doses and dose range are
provided in Table 1. Non-responsiveness to an SRI was
defined as either an improvement score on the clinical
global impression scale of minimally improved (3) or
worse (4,5,6), or less than 25% reduction in Yale BrownPage 2 of 8
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treatment. Inadequate response, as defined above, to at
least one SRI administered for a minimum of 12 weeks of
which 6 weeks was either at the maximum tolerated dose
or alternatively the manufacturer's recommended maxi-
mum daily dose. SRI doses were maintained at the same
level throughout the double-blind treatment phase. For
assignment to either quetiapine or placebo groups, we
used a computer generated randomization schedule sup-
plied by the sponsoring pharmaceutical company which
also packaged the medication. This procedure ensured
blinded, balanced allocation to each treatment group
across all the study sites. All investigators remained blind
to this schedule until closure of the study. No incidents
requiring investigators to break the blind occurred
through the course of the study.
Treatment
At baseline participants were randomly allocated to
receive treatment with either quetiapine or placebo using
a computer generated schedule and numbered dispensing
wallets. A flexible dosing schedule was initiated at 25 mg
per day for one week and then doubled weekly to the start
of week 4. Based on Clinical Global Impression of
Improvement (CGI-I) scores of minimally improved or
worse, clinicians were permitted to increase the dose to a
maximum of 300 mg per day for the final two weeks of the
study. In addition to clinical measures of improvement,
clinicians also considered patient tolerability in their deci-
sion to adjust doses. Following completion of the treat-
ment phase, subjects were withdrawn from study
medication while continuing their SRIs. All subjects were
then followed up for any adverse effects.
Ratings
Patients were assessed by clinicians at baseline and on
completion of weeks 2, 4 and 6. Telephonic assessments
were performed on completion of weeks 1 and 3. Symp-
toms of obsessive-compulsive disorder were measured by
the same clinician where possible at all study visits using
the Yale Brown Obsessive Compulsive Scale YBOCS)
[30,31]. A global assessment of severity and improvement
was made by clinicians at all assessment points using the
Clinical Global Impressions scale of Severity (CGI-S) and
Improvement (CGI-I) [32]. Depression was rated using
the 10-item Montgomery-Asberg Depression rating scale
(MADRS) [33]. For a measure of patient-rated disability
we used the Sheehan Disability scale (SDS) [34]. For sub-
jects with tics, frequency and severity were rated using the
Yale Global Tic Severity Scale (YGTSS) [35].
Our primary outcome measures for OCD symptoms were
(1) the change in YBOCS score from baseline to endpoint
and (2) the clinical global impression of improvement
(CGI-I) at endpoint. In the final analysis, treatment
response was defined as a 25% or greater reduction in
YBOCS score and a CGI-I of 1 (very much improved) or 2
(much improved) from baseline to endpoint. Secondary
outcome measures included the MADRS, SDS and YGTSS
(in subjects with co-morbid tics).
Statistical analysis
Thirty-nine of the forty-two randomised subjects success-
fully completed the six-week treatment phase. Two sub-
jects withdrew from the study prematurely (Week 1 and
Week 4) due to severe levels of sedation. In both of these
cases at least one week of study medication had been
taken and at least one post-baseline clinical assessment
was completed. Both of these subjects were included in
the final analysis using data from the last observation car-
ried forward (LOCF). The single subject not included in
the efficacy analysis completed the study, but was found
not to have correctly fulfilled the study definition of treat-
ment refractoriness and was excluded. Twenty subjects
were allocated to the quetiapine arm and twenty-one to
the placebo arm. Student's t-tests were used to determine
any baseline differences in the groups for age, gender,
number of previous trials of SSRI's, severity of symptoms
in relation to OCD, depressive symptoms, and CGI-S.
Analysis of variance was undertaken with group and tics as
factors. All tests were two-tailed with p-values of less than
0.05 considered significant.
Table 1: SRI's used by subjects for failed treatment trial prior to inclusion in the study.
Drug N Mean maximum tolerated dose (mg/day) Median daily dose (mg/day) Range
Fluoxetine 13 60 60 60
Citalopram 10 61 60 10
Paroxetine 4 65 60 20
Fluvoxamine 10 290 300 100
Sertraline 1 200 200 0
Clomipramine 2 250 250 0Page 3 of 8
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Study sample characteristics
For the final analysis, our sample comprised 19 men and
22 women. Baseline characteristics of two treatment
groups did not differ with respect to age (years) (quetiap-
ine group 33.8(SD 9.66), placebo group 31.81 (SD
12.14); p = 0.57), gender (p = 0.29), number of previous
adequate SRI trials (quetiapine 1.55 (SD 1), placebo 1.62
(SD 1.02) (p = 0.83), baseline severity of OCD (CGI-
severity, p = 0.47; YBOCS, p = 0.33), depressive symptoms
(p = 0.91), patient-rated disability (p = 0.28) or the pres-
ence (n = 11, p = 0.66 and severity (p = 0.87) of co-morbid
tics.
Treatment outcomes
For the primary outcome measure of severity (YBOCS),
quetiapine (p < 0.0001) and placebo (p = 0.001) augmen-
tation of an SRI significantly improved symptoms of
OCD. However quetiapine did not demonstrate signifi-
cant benefit over placebo at the end of the six-week treat-
ment period (F = .19; p = .636) (Figure 1). The mean
reduction in YBOCS scores for the combined group was
7.15 points (quetiapine = 7.10; placebo 7.19). Forty per-
cent (n = 8/20) of subjects on quetiapine were classified as
responders (YBOCS reduction of >25% from baseline and
CGI-improvement score of 1 or 2) while 47.6% (n = 10/
21) of subjects on placebo were classified as responders. A
higher number of previous SRI trials for the each treat-
ment group did not correlate with the degree of change on
the YBOCS or the response status. Table 2 provides details
of individual subject SRI doses, baseline clinical severity
ratings and response status. Table 3 provides a summary
of baseline and change scores for each of the primary and
secondary outcome variables.
Of the 11 subjects with co-morbid tics, six were ran-
domised to quetiapine. Endpoint data was missing for
one subject on quetiapine. Of the remaining 10 subjects,
3 (quetiapine n = 2 (33%); placebo n = 1(20%)) were clas-
sified as YBOCS responders. The reduction in the YGTSS
did not differ significantly between treatment groups with
tics (quetiapine -4.5, placebo -9.4; F = 2.8, p = .46).
Severity ratings for depressive symptoms (MADRS) were
low at baseline (mean 10.6, SD 4.8), showed little change
over the study period, and at week 6 remained similar for
YBOCS change for treatment groupsFigure 1
YBOCS change for treatment groups Quetiapine and placebo groups improved significantly, without significant between 
group differences (F = 0.19; p = 0.636)
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6.1).
The mean daily dose at week 6 for the quetiapine group
was 168.75 mg (SD 120.82) compared to 228.57 mg (SD
99.46) per day for those on placebo. Quetiapine respond-
ers (187.5 mg, SD 124.6) did not differ significantly from
quetiapine non-responders (156.25 mg, SD 122.1) in
their mean daily dose at Week 6 (p = .585). Furthermore,
within the quetiapine group, participants receiving ≥ 200
mg/day (10/20 at week 6 demonstrated non-significant
differences (F = 6.837, p = .988) and a marginally lower
percentage reduction in YBOCS at endpoint (26.7%, SD
20.34) compared to those receiving a dose ≤ 200 mg/day
(26.9%, SD 36.24) at endpoint.
Table 2: Baseline characteristics of treatment groups
Treatment 
Group
SRI baseline SRI Dose 
baseline 
(mg/day)
Previous 
SRI trials
Total 
YBOCS – 
Baseline
Total 
YBOCS – 
Week 6
Endpoint 
dose 
(mg/day)
% 
CHANG
E
CGI – 
Improve
ment
Response 
status
Quetiapine 1 Paroxetine 60 1 33 29 50 -12.00 3 N/R
2 Citalopram 60 2 25 23 200 -8.00 4 N/R
3 Fluvoxamine 300 1 32 27 300 -16.00 3 N/R
4 Citalopram 70 1 27 25 25 (E/W)* -7.00 4 N/R
5 Clomipramine 250 2 22 27 100 23.00 5 N/R
6 Paroxetine 60 5 35 32 300 -9.00 4 N/R
7 Fluoxetine 80 3 25 16 300 -36.00 2 R
8 Sertraline 200 1 18 3 50 -83.00 1 R
9 Fluoxetine 20 1 21 20 300 -5.00 4 N/R
10 Fluoxetine 60 1 22 17 300 -23.00 2 N/R
11 Citalopram 60 1 32 17 300 -47.00 1 R
12 Fluoxetine 80 1 32 14 300 -56.00 1 R
13 Fluvoxamine 300 1 30 12 50 -60.00 1 R
14 Fluoxetine 60 1 25 7 50 -72.00 1 R
15 Citalopram 60 1 27 24 200 -11.00 4 N/R
16 Fluvoxamine 300 1 24 12 150 -50.00 2 R
17 Fluvoxamine 200 2 22 22 50 .00 4 N/R
18 Fluvoxamine 300 2 25 22 25 -12.00 4 N/R
19 Fluoxetine 60 2 24 25 25 (E/W)* 4.00 4 N/R
20 Clomipramine 250 2 27 12 300 -56.00 2 R
Placebo 1 Fluvoxamine 300 2 32 25 300 -22.00 3 N/R
2 Fluvoxamine 300 1 30 28 300 -7.00 3 N/R
3 Fluoxetine 80 2 34 38 300 12.00 4 N/R
4 Paroxetine 60 1 22 18 300 -18.00 1 N/R
5 Citalopram 60 1 28 26 300 -7.00 4 N/R
6 Fluoxetine 60 5 26 24 300 -8.00 3 N/R
7 Fluoxetine 60 1 23 23 300 .00 4 N/R
8 Fluoxetine 60 1 27 10 300 -63.00 1 R
9 Fluoxetine 40 1 32 18 300 -44.00 2 R
10 Citalopram 60 2 24 23 300 -4.00 4 N/R
11 Citalopram 60 1 35 23 300 -34.00 2 R
12 Fluvoxamine 300 3 22 14 300 -36.00 2 R
13 Citalopram 60 1 28 10 50 -65.00 2 R
14 Fluoxetine 60 1 28 4 50 -86.00 2 R
15 Citalopram 60 1 26 19 100 -27.00 2 R
16 Fluoxetine 60 1 27 12 100 -56.00 1 R
17 Fluoxetine 20 1 26 18 200 -31.00 2 R
18 Fluvoxamine 300 2 23 35 200 52.00 6 N/R
19 Citalopram 60 2 26 9 100 -65.00 2 R
20 Paroxetine 80 1 32 29 300 -9.00 3 N/R
21 Fluvoxamine 300 3 31 25 100 -19.00 2 N/R
*E/W = Early withdrawalPage 5 of 8
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Quetiapine was generally well tolerated and no serious
adverse events (SAE's) were reported through the course
of the study period. Two patients on quetiapine withdrew
from the study due to severe sedation (Week 1 and Week
4) that was judged to be drug related. Otherwise adverse
events were in the mild to moderate range and were
mostly self-limiting. No subjects on placebo withdrew
from the study. Table 4 provides a list of the adverse
events and their frequencies in the respective study
groups.
Discussion
Our findings indicate that both quetiapine and placebo
significantly reduced symptoms in subjects with OCD
who had failed to respond adequately to 12 weeks of an
SSRI and, that the difference between groups was not sig-
nificant. Similarly in the subgroup with co-morbid tics, no
preferential benefit was noted for quetiapine. Interest-
ingly, the high placebo response was similar to that seen
in a recent failed controlled trial of olanzapine [25], but
stands in contrast to the positive studies in this area in
which low placebo response rates were seen when demon-
strating efficacy of quetiapine [23], risperidone [21], and
olanzapine [24]. It is likely that features of study design or
specific study population characteristics may have con-
tributed to this finding and these are discussed below.
First, the duration of a therapeutic trial of an SRI prior to
augmentation with an antipsychotic should be of ade-
quate dose and duration. In our study the majority of par-
ticipants had failed only the single trial of an SRI on which
they continued during the study (63.4% mean 1.59).
Notably only six weeks of this treatment was required at
the maximum tolerated dose. Despite the notion that an
optimum trial of pharmacotherapy in OCD is 12 weeks, it
may be argued that higher and ultimately effective doses
of an SRI had not been maintained for an optimum
duration prior to randomization. Given that therapeutic
doses of SRIs in OCD are usually on the upper end of the
dose range, it seems feasible that the high placebo
response rate may reflect a response to SRI's once they had
been administered at these higher doses for the additional
six weeks of the study. It seems possible that the recent
study by Shapira et al [25] may have been impacted by
similar factors.
Table 3: Summary scores (baseline) and change scores for primary and secondary outcome variables.
Quetiapine Placebo
YBOCS (baseline) 26.4 (SD4.6) 27.7(SD3.9)
YBOCS (change at week 6) -7.1(SD7.2) -7.2(SD8.4)
YBOCS % change -26.9% -26%
CGI-Severity (baseline) 5.2 (SD0.8) 5.3 (SD0.8)
CGI-Severity (week 6) 4.1 (SD1.4) 4.1(SD1.5)
MADRS (baseline) 10.6 (SD 4.8) 10.71 (SD 9.8)
MADRS (change at week 6) -2.6 (SD 6.5) -3 (SD 8.3)
SDS (baseline) 17.9 (SD 5.3) 19.6(SD4.7)
SDS (change at week 6) -5.3(SD5.6) -6.1 (SD4.8)
YGTSS (baseline) 24.7 (SD 19.3) 22.6(SD 22.3)
YGTSS (change at week 6) -4.5(SD 5.1) -9.4 (SD 14.6)
YGTSS % change -18.2% -41.6%
Table 4: Percentage of subjects for each treatment group 
reporting adverse events
Adverse event Quetiapine (%, n) Placebo (%, n)
Sedation 75% (15) 33.3%(7)
Dry mouth 15% (3) 0
Headache 15% (3) 38% (8)
Fatigue 15% (3) 19% (4)
Irritability 10% (2) 4.7% (1)
Impaired 
concentration
10% (2) 0
Dizziness 5% (1) 14.3% (3)
Nausea 5% (1) 9.5% (2)
Increased appetite 5% (1) 9.5% (2)
Delayed ejaculation 5% (1) 0
Weight gain 5% (1) 0
Worsening mood 5%(1) 4.7%(1)
Memory difficulties 5%(1) 0
Muscle aches 5%(1) 0
Abdominal 
tenderness
5%(1) 0
Slurred speech 5%(1) 0Page 6 of 8
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trials in the subgroup receiving quetiapine did not predict
a poorer response to treatment. This effect is probably
related to the lack of statistical power to detect these dif-
ferences in a group in which the low number of previous
SRI trials was a distinguishing characteristic. Certainly,
previous positive studies in this area have used relatively
more refractory groups based on the number of previously
failed SRI trials. Taken together with the first point above,
we suggest that future work in this area should consider
longer periods at maximum tolerated doses of SRI's prior
to categorisation of subjects as treatment refractory.
Third, the use of a slow up-titration resulted in a relatively
low mean daily dose being administered for the majority
of the study. For instance, a mean daily (week 6) dose of
168 mg/day in the quetiapine group (median 175 mg)
had only been achieved for the final two weeks of the
study. These doses are comparably low to those used in
the negative single-blind study using low dose quetiapine
by Sevincok et al [19]. In contrast the positive study using
quetiapine by Denys et al [23] employed a more rapid up-
titration and a fixed-dose design. This meant that subjects
were exposed to 200 mg daily doses that were generally
well tolerated, from the start of week 3. The authors of this
study were able to show significant YBOCS differences
between groups from the end of week 4. Similarly Mc
Dougle et al [21], using risperidone, began treatment on 1
mg per day for one week and permitted weekly 1 mg incre-
mental increases for 6 weeks. They found that by the
beginning of week 2, most subjects were on or around the
mean daily dose for treatment responders (2.2 mg).
Despite the significant improvement in the quetiapine
group demonstrated in our study, the apparent lack of
benefit of doses higher than 200 mg per day may seem
surprising, however, we cannot rule out the possibility
that administering these higher doses for an adequate
duration would have changed the outcome. In addition it
must be noted that in our study the quetiapine group
reported high rates of sedation (n = 15, 75%) and a 10%
(n = 2) rate of premature withdrawal was experienced. As
such it seems likely that a more aggressive up-titration
schedule might have resulted in even higher rates of with-
drawal. By comparison, rates of sedation were equally
high, but did not appear to restrict use of the more rapid
up-titration in the study by Denys et al [23]. Certainly evi-
dence of efficacy using lower doses has been demon-
strated in studies of 6 and 8 weeks duration [21,23,24],
and it seems that therapeutically adequate doses should
probably be reached earlier than week 4 in a 6 week study.
Fourth, the impact of repeated clinical assessments and
rating of relatively small changes in clinical severity com-
bined with regular dose increases, may conceivably have
increased the placebo response rates resulting from
increased optimism, a tendency to over-report improve-
ments and belief that higher doses are more likely to be
more effective than lower doses. This may be particularly
true for the placebo-treated group that were considerably
less likely to report sedation as an adverse event and as
such were more likely to have their treatment dose
increased at each visit. Our results differ, with respect to
placebo response, from a considerable literature that sug-
gests a consistently lower placebo response rate in treat-
ment trials in OCD than in other mood and anxiety
disorders. While we believe that the reasons (1–3) dis-
cussed above probably provide the main reasons for our
finding, the impact of repeated assessments and the
potential effect thereof cannot be entirely discounted.
Conclusions
Despite significant improvement in each of the study
groups, response to quetiapine augmentation in SRI non-
responders, failed to separate from placebo treated sub-
jects at the end of the six week treatment phase. A number
of limitations in study design make comparisons with pre-
vious studies in this area difficult and probably contrib-
uted to our negative findings. Future work in this
important clinical area should address these limitations.
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